Applications of (-)-N-Methylephedrine in Industrial Manufacturing

As a direct producer of (-)-N-Methylephedrine, we supply this high-purity chiral amine to specialized sectors requiring precise functional group chemistry and validated process controls. Explore practical downstream application scenarios with real industry standards, formulation parameters, and integration benchmarks.

1. Pharmaceutical Chiral Intermediate Synthesis

Pharmaceutical manufacturers integrate (-)-N-Methylephedrine as a critical chiral auxiliary for enantioselective synthesis of beta-adrenergic agonists, antihistamines, and certain anti-asthmatic agents. Its optical purity and secondary amine functionality allow chemists to achieve high enantiomeric excess in chiral center construction, meeting the stringent requirements of API manufacturing pipelines. Using tightly specified GMP-compliant grades, customers demand validated documentation for every production lot, particularly when producing actives for regulated markets.

Industry compliance standards

• ICH Q7: Good Manufacturing Practice for Active Pharmaceutical Ingredients
• European Pharmacopoeia (Ph. Eur.) quality monograph for starting materials
• 21 CFR Part 211 (US FDA cGMP for Finished Pharmaceuticals)
• Japanese Pharmacopoeia standards for pharmaceutical intermediates

Typical usage ratio

• 0.8 – 1.5 molar equivalents relative to target prochiral substrate, adjusted to maximize yield and stereoselectivity while minimizing wastage in post-reaction recovery

Downstream process integration

• Added as a key chiral auxiliary during initial enantioselective synthesis step
• Recovered and recycled via acid-base extraction after chiral resolution or alkylation
• Complete in-process controls with in-line chiral HPLC verification

Final product types

• Chiral pharmaceutical intermediates (e.g., for beta-adrenergic agonists like Salbutamol, antihistamines, bronchodilators)
• Enantiopure active pharmaceutical ingredients (APIs) after subsequent transformation

2. Asymmetric Catalysis (Ligand Manufacturing)

Producers of asymmetric catalysts and ligands utilize (-)-N-Methylephedrine as a foundational chiral building block, especially in the construction of oxazoline, salen-type, and phosphine ligands. Its defined stereochemistry allows for fine-tuning of transition metal-catalyzed transformations, supporting customers in agrochemical and fine chemical development. Sourcing demands prioritization of full traceability, routinely documented in GMP intermediate dossiers for non-GMP tools as well.

Industry compliance standards

• ISO 9001:2015 certified manufacturing systems for fine chemicals
• Custom-specific specifications (NMR, chiral GC/HPLC, enantiomeric excess certification)
• Supply agreements require full traceability of chirality origin and batch history
• European REACH registration for safe handling in catalyst supply chains

Typical usage ratio

• 1.0 molar equivalent per ligand scaffold (by substitution in targeted ligand synthesis)

Downstream process integration

• Condensed with carboxylic acids or isocyanates in ligand assembly reactions
• Incorporated into metal-ligand complex synthesis via controlled addition under inert atmosphere
• Included in resin-bound or solid-phase catalyst construction steps

Final product types

• Chiral ligands for transition metal catalysis (e.g. bidentate or tridentate auxiliaries)
• Palladium, copper, and rhodium asymmetric catalysts
• Pre-packed chiral catalytic cartridges for high-throughput screening

3. Laboratory Chemical Synthesis (Research & CRO Supply)

Contract research organizations and advanced research laboratories rely on (-)-N-Methylephedrine for the synthesis of enantiomerically enriched reference compounds and analytical standards. Its chirality enables stereoselective derivatizations and the preparation of calibration standards for chiral separation validation. High-purity grades support exacting documentation demands and facilitate reliable use in multi-step synthetic campaigns, where change control compliance drives supplier selection.

Industry compliance standards

• GLP (Good Laboratory Practice) for non-human research material preparation
• ISO/IEC 17025 accreditation for analytical reference material production
• Certificate of Analysis (including chiral purity, water, and residual solvent profiles)
• Custom batch traceability on per-project basis

Typical usage ratio

• 0.5 – 2.0 equivalents, defined by protocol needs and often specified per experimental batch scale

Downstream process integration

• Charged at stereocenter-introduction stage of synthetic sequence
• Routinely used for calibration or preparation of comparator enantiomers in chiral analysis
• Residual derivatization steps for final analytical standard isolation

Final product types

• Enantiopure research chemicals
• Stereospecific analytical standards for chiral chromatography
• Custom reference compounds for non-regulated R&D applications

4. Methylephedrine-Based Expectorant Formulations (Active Ingredient)

In certain regulated Asia-Pacific markets, downstream pharmaceutical companies formulate expectorant cough syrup and tablet products using (-)-N-Methylephedrine as the principal active ingredient. These application contexts require pharmacopoeial grade supply, mandatory impurity profiling, and robust documentation according to regionally approved drug master files. Close regulatory alignment drives manufacturing controls and batch release under strict GMP oversight.

Industry compliance standards

• Japanese Pharmacopoeia (JP) monograph for Methylephedrine Hydrochloride
• Japanese GMP Ministerial Ordinance (Ministry of Health, Labour and Welfare)
• Korean Pharmacopoeia standards and relevant food-drug coexistence regulations
• Lot-specific Drug Master File (DMF) registration or submission

Typical usage ratio

• 0.02 – 0.06% w/v in finished syrup or up to 25 mg/tab in tablet formulations, based on local regulatory maximum allowable daily dose stipulations

Downstream process integration

• Dissolved directly in aqueous phase with sweetener and stabilizer, cold blend prior to filtration
• Compressed with auxiliary excipients during direct compression tablet manufacturing
• QC release includes assay, related substance, and microbiological controls as per regional pharmacopoeia

Final product types

• Expectorant oral syrups (OTC and prescription)
• Cough suppressant tablets and combination cold remedies

5. Chiral Resolving Agent in Amino Acid & Alkaloid Production

Producers focused on enantiopure amino acids and natural product derivatives use (-)-N-Methylephedrine as a resolving agent, taking advantage of its stereochemical complementarity to preferentially crystallize specific enantiomers from racemic mixtures. Detailed batch documentation and chiral analytical support remain critical, especially when supplying food-grade or pharmaceutical-grade ingredients into mature regulatory systems.

Industry compliance standards

• Food Chemicals Codex (FCC) for resolving agents if used in food amino acid workflows
• Pharmacopoeia standards for pharmaceutical-grade amino acid APIs and intermediates
• FSSC 22000 (Food Safety System Certification) and ISO 9001 in relevant facilities
• Allergen and TSE/BSE-free declarations for Europe/US food supply chains

Typical usage ratio

• Variable, typically 1.0–1.2 equivalents relative to racemic substrate, optimized for solubility and resolution efficiency on pilot and plant scale

Downstream process integration

• Solution mixing followed by seeding, slow cooling and controlled crystallization in jacketed vessels
• Filtration, washing, and post-crystallization purification with analytical verification of enantiomeric purity
• Resolving agent recovery via pH-controlled extraction or back-neutralization

Final product types

• Enantiomerically pure amino acids (e.g., phenylalanine, tryptophan)
• Natural alkaloids and bioactive molecule derivatives
• Chiral building blocks for nutraceutical and pharmaceutical downstream use